A Houston-based company that's on a mission to the moon has a new control center. Photo via Jesus Motto/Savills

A space tech startup based in Clear Lake, just outside of Houston, has a new office that's going to help them take their technology out of this world.

Intuitive Machines, an engineering firm specializing in automation and aerospace, has upgraded its Houston-area control center. The company has moved into a 22,300-square-foot space on the sixth floor of a building located at 3700 Bay Area Road. The lease was executed last fall. London-based Savills had a Houston team to represent the tenant and oversee project management of the buildout.

"I was proud to work on the build-out for Intuitive Machines during such an exciting time in its history," says Savills associate director, David Finklea, in a news release. "As Intuitive is a leader in the aerospace space field, we created an environment that is far from the industry standard and complements its innovative endeavors. The design is bright and contemporary, with a relaxing and airy feel that imitates the illusion of being in space."

Currently, Intuitive Machines is working on NASA's Artemis Program and has been granted $77 million from the organization to launch a flight to the moon next year. In light of this project, Intuitive Machines needed a larger, optimized space to support its growing team.

Finklea and Derrell Curry, executive vice president at Savills, teamed up with architecture firm CDI Douglass Pye Inc. on the project that took elements from the company's former first-floor office and created a new design aesthetic that "evoked the neutral colors of the lunar landscape," according to the release.

"Despite the current COVID-19 pandemic and delays caused as a result, we were able to complete the space within six months through close coordination with Intuitive Machines, CDI Douglass Pye, and the landlord," Finklea says in the release. "Everyone came together to ensure the new headquarters was delivered promptly for Intuitive Machines to prepare for its historic mission that further solidifies the future of privatized space travel."

The unique control center is circular, which optimizes collaboration, and equipped with a large curved monitor. The office is also hooked up to emergency backup power — something the team needs as it continues on its mission to the moon.

"I couldn't be more pleased with Derrell and David and the team they put together to create our new headquarters. Everyone demonstrated a high level of professionalism and attention to detail that produced a workplace that truly represents Intuitive Machines as an innovative lunar space systems company," says Steve Altemus, president and CEO of Intuitive Machines, in the release. "Thank you to Savills, CDI Douglass Pye, and Byrd Construction for delivering an exceptional space that allows us to conduct our mission to the moon from our new control center right here in Houston!"

Intuitive Machines moved into a new space. Photo via Jesus Motto/Savills

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Nominations are now open for the 2025 Houston Innovation Awards

Calling All Innovators

Calling all Houston innovators: The Houston Innovation Awards return this fall to celebrate the best and brightest in the Houston innovation ecosystem right now.

Presented by InnovationMap, the fifth annual Houston Innovation Awards will take place November 5 at TMC Helix Park.

The awards program will honor the top startups and innovators in Houston across 10 categories, and we're asking you to nominate the most deserving Houston innovators and innovative companies today.

This year's categories are:

  • Minority-founded Business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation.
  • Female-founded Business, honoring an innovative startup founded or co-founded by a woman.
  • Energy Transition Business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond.
  • Health Tech Business, honoring an innovative startup within the health and medical technology sectors.
  • Deep Tech Business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics, and space sectors.
  • Startup of the Year (People's Choice), honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an interactive voting experience.
  • Scaleup of the Year, honoring an innovative later-stage startup that's recently reached a significant milestone in company growth.
  • Incubator/Accelerator of the Year, honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups.
  • Mentor of the Year, honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs.
  • Trailblazer, honoring an innovator who's made a lasting impact on the Houston innovation community.

Nominations may be made on behalf of yourself, your organization, and other leaders in the local innovation scene. The nomination period closes on August 31, so don't delay — nominate today at this link, or fill out the embedded form below.

Our panel of esteemed judges will review the nominations, and determine the finalists and winners. Finalists will be unveiled on September 30, and the 2025 Houston Innovation Awards winners will be announced live at our event on November 5.

Tickets will go on sale this fall. Stay tuned for that announcement, as well as more fanfare leading up to the 2025 Houston Innovation Awards.

Nominate now:

Interested in Innovation Awards sponsorship opportunities? Please contact sales@innovationmap.com.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."